(0.57%) 5 075.50 points
(0.32%) 38 192 points
(0.80%) 17 578 points
(0.96%) $79.76
(2.33%) $1.977
(0.06%) $2 312.40
(-0.39%) $26.65
(0.59%) $960.50
(0.19%) $0.935
(0.50%) $11.08
(0.10%) $0.799
(-1.50%) $91.86
5 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 5.91%
1.37% $ 94.15
@ $94.03
Emitido: 1 may 2024 @ 15:38
Retorno: 0.13%
Señal anterior: may 1 - 13:29
Señal anterior:
Retorno: 1.05 %
Live Chart Being Loaded With Signals
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle...
Stats | |
---|---|
Volumen de hoy | 995 767 |
Volumen promedio | 1.38M |
Capitalización de mercado | 11.22B |
EPS | $0 ( 2024-02-28 ) |
Próxima fecha de ganancias | ( $-0.700 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -21.06 |
ATR14 | $3.96 (4.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-29 | Fesko John | Sell | 929 | Common Stock |
2024-04-29 | Moshkevich Solomon | Sell | 1 196 | Common Stock |
2024-04-29 | Rabinowitz Daniel | Sell | 1 057 | Common Stock |
2024-04-29 | Chapman Steven Leonard | Sell | 4 084 | Common Stock |
2024-04-29 | Brophy Michael Burkes | Sell | 1 238 | Common Stock |
INSIDER POWER |
---|
-50.19 |
Last 100 transactions |
Buy: 166 671 | Sell: 498 049 |
Volumen Correlación
Natera Inc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Natera Inc Correlación - Moneda/Commodity
Natera Inc Finanzas
Annual | 2023 |
Ingresos: | $1.08B |
Beneficio Bruto: | $492.74M (45.52 %) |
EPS: | $-3.78 |
FY | 2023 |
Ingresos: | $1.08B |
Beneficio Bruto: | $492.74M (45.52 %) |
EPS: | $-3.78 |
FY | 2022 |
Ingresos: | $820.22M |
Beneficio Bruto: | $363.97M (44.37 %) |
EPS: | $-5.57 |
FY | 2021 |
Ingresos: | $625.49M |
Beneficio Bruto: | $307.07M (49.09 %) |
EPS: | $-5.21 |
Financial Reports:
No articles found.
Natera Inc
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico